Sign in to confirm you’re not a bot
This helps protect our community. Learn more

Introduction

0:00

Phase 3 trials for a coronavirus vaccine will start July. Could you talk a little bit about what that will look like?

0:32

The Moderna, phase 2 trial, how large is that, and what will be learned from the phase 2 before we get to the phase 3 in July?

2:12

How long does a phase 3 trial need to last to know if there's effectiveness?

2:36

Will there be age, sex, race, ethnicity, diversity amongst the 30,000 trial participants, or will it be focused on healthy, younger individuals?

3:40

Are you optimistic based on the acceleration in vaccine development over the past few years and how quickly we've been able to get to phase 3 trials?

4:08

What happens with the production of that candidate vaccine? Will there be enough doses available in the fall?

6:05

Can you see a role for monoclonal antibodies, as we try to sort out schools and colleges, protecting the elderly, and nursing home residents?

7:50

Will there be a sufficient amount of convalescent plasma available?

8:58

Vitamin D and whether or not it could be helpful in treatment of COVID-19.

9:24

Zinc and azithromycin

11:07

Do you have a sense of what's happening in the states that have opened up early?

12:21

Immunity passports

14:15

Opening schools safely in the fall.

15:14

Asymptomatic spread

17:14

IgG and IgM antibodies

18:55

Remembering AIDS activist Larry Kramer

20:23

Your equanimity. Does it come from your parents? Does it come from your Jesuit education? It's extraordinary under the face of just remarkable and unfair criticisms.

25:55
Coronavirus Q&A With Anthony Fauci, MD – June 2, 2020
NIAID Director Anthony Fauci discusses recent developments in the global COVID-19 pandemic with JAMA Editor Howard Bauchner. Recorded on June 2, 2020. • Earn Free CME credits by watching JAMA Livestreams and completing a brief questionnaire. Claim 0.5 credits for each video at https://ja.ma/covidqa • Coronavirus Resource page from the JAMA Network: https://ja.ma/covidyt ===================================================================== To watch all the #JAMALive Q&A's Visit: https://ja.ma/covidqaytpl Don't forget to hit subscribe or click https://ja.ma/subscribe #JAMALive #Coronavirus #SARSCoV2 --------------------------------------------------------------------------------- For more from JAMA • https://www.jama.com  / jamajournal    / jama_current    / jamanetwork   Follow the #JAMANetworkhttps://www.jamanetwork.comhttp://www.jamanetworkaudio.com  / jamanetwork    / jamanetwork    / jamanetwork    / jamanetwork   Topics discussed in this intervew: 0:00 Introduction 0:32 Phase 3 trials for a coronavirus vaccine will start July. Could you talk a little bit about what that will look like? 2:12 The Moderna, phase 2 trial, how large is that, and what will be learned from the phase 2 before we get to the phase 3 in July? 2:36 How long does a phase 3 trial need to last to know if there's effectiveness? 3:40 Will there be age, sex, race, ethnicity, diversity amongst the 30,000 trial participants, or will it be focused on healthy, younger individuals? 4:08 Are you optimistic based on the acceleration in vaccine development over the past few years and how quickly we've been able to get to phase 3 trials? 6:05 What happens with the production of that candidate vaccine? Will there be enough doses available in the fall? 7:50 Can you see a role for monoclonal antibodies, as we try to sort out schools and colleges, protecting the elderly, and nursing home residents? 8:58 Will there be a sufficient amount of convalescent plasma available? 9:24 Vitamin D and whether or not it could be helpful in treatment of COVID-19. 11:07 Zinc and azithromycin 12:21 Do you have a sense of what's happening in the states that have opened up early? 14:15 Immunity passports 15:14 Opening schools safely in the fall. 17:14 Asymptomatic spread 18:55 IgG and IgM antibodies 20:23 Remembering AIDS activist Larry Kramer 25:55 Your equanimity. Does it come from your parents? Does it come from your Jesuit education? It's extraordinary under the face of just remarkable and unfair criticisms.

Follow along using the transcript.

JAMA Network

226K subscribers